Alex Thompson
Stock Analyst at Stifel
(1.20)
# 3,337
Out of 4,818 analysts
33
Total ratings
46.15%
Success rate
-11.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| THRD Third Harmonic Bio | Downgrades: Hold | $23 → $5 | $5.15 | -2.91% | 2 | Mar 28, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $4.95 | +627.27% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $32.49 | +84.70% | 1 | Mar 25, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $200 → $207 | $158.46 | +30.63% | 2 | Nov 15, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $10.62 | +361.39% | 1 | Oct 11, 2024 | |
| ARGX argenx SE | Maintains: Buy | $485 → $500 | $594.65 | -15.92% | 4 | Jun 24, 2024 | |
| SYRE Spyre Therapeutics | Reiterates: Buy | $36 → $54 | $14.29 | +277.89% | 2 | Mar 26, 2024 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | $44 | $21.75 | +102.30% | 1 | Feb 15, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Hold | $6 → $2 | $1.15 | +73.91% | 5 | Dec 18, 2023 | |
| TVTX Travere Therapeutics | Maintains: Hold | $8 → $10 | $16.68 | -40.05% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $39.58 | +74.33% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $1.20 | -16.32% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $13.55 | +195.31% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $0.87 | +4,483.48% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $14.45 | +135.38% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.55 | +2,029.03% | 1 | Dec 14, 2022 |
Third Harmonic Bio
Mar 28, 2025
Downgrades: Hold
Price Target: $23 → $5
Current: $5.15
Upside: -2.91%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $4.95
Upside: +627.27%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $32.49
Upside: +84.70%
Ascendis Pharma
Nov 15, 2024
Maintains: Buy
Price Target: $200 → $207
Current: $158.46
Upside: +30.63%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $10.62
Upside: +361.39%
argenx SE
Jun 24, 2024
Maintains: Buy
Price Target: $485 → $500
Current: $594.65
Upside: -15.92%
Spyre Therapeutics
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $14.29
Upside: +277.89%
Dianthus Therapeutics
Feb 15, 2024
Initiates: Buy
Price Target: $44
Current: $21.75
Upside: +102.30%
Ventyx Biosciences
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $1.15
Upside: +73.91%
Travere Therapeutics
Dec 18, 2023
Maintains: Hold
Price Target: $8 → $10
Current: $16.68
Upside: -40.05%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $39.58
Upside: +74.33%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $1.20
Upside: -16.32%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $13.55
Upside: +195.31%
Aug 9, 2023
Initiates: Buy
Price Target: $40
Current: $0.87
Upside: +4,483.48%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $14.45
Upside: +135.38%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.55
Upside: +2,029.03%